Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that MSI-H status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Colorectal Adenocarcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.

This statement is based on a regulatory approval from the Health Service Executive:

Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.

Citation

Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6385/551_Nivolumab_3mgkg_Ipilimumab_1mgk.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2023-06-01	Health Service Executive	Indication approved for reimbursement.